Skip to main
CSTL
CSTL logo

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. has demonstrated a solid financial performance, marked by an increase in revenue estimates and the raising of FY24 revenue guidance to a range of $320 million to $330 million due to strong results across its product offerings. The company reported a significant year-over-year increase of 81% in test volume for the IDgenetix test, highlighting its unique position in the marketplace and the favorable traction for its diagnostic solutions designed for a variety of cancers. Additionally, consistent commercial execution, recent acquisitions, and positive reimbursement decisions for newer products underline the growth potential in the dermatologic and gastroenterology markets, contributing to an optimistic outlook for the company.

Bears say

Castle Biosciences Inc faces several fundamental challenges that contribute to a negative outlook for its stock. The company heavily relies on government and commercial reimbursement rates for its diagnostic tests, which are susceptible to fluctuations, potentially impacting revenue stability. Furthermore, there are concerns regarding competition for new products, the risk of underperformance in tests currently under development, and the firm's historical pattern of operating at losses, raising the likelihood for additional capital requirements that may not be attainable.

CSTL has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Buy based on their latest research and market trends.

According to 10 analysts, CSTL has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.